SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
SPECTA
1 other identifier
observational
4,975
19 countries
133
Brief Summary
SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer patients to support biospecimen-based translational research and clinical cancer research, including biomarker discovery to improve the understanding of tumor biology and cancer patients care.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2017
Longer than P75 for all trials
133 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 13, 2016
CompletedFirst Posted
Study publicly available on registry
July 15, 2016
CompletedStudy Start
First participant enrolled
May 3, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 29, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2031
ExpectedApril 17, 2026
April 1, 2026
5.3 years
July 13, 2016
April 14, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
To establish a quality assured platform to improve the understanding of tumor biology and cancer patients care
material (including imaging data) as well as patient-reported outcomes from patients with cancer diagnosis to support biospecimen-based translational research and biomarker discovery to improve the understanding of tumor biology and cancer patients care.
5 years
Secondary Outcomes (7)
To perform biospecimen and data based high quality research aiming to better understand the biology of cancer, and/or how it is currently managed and/or how to better diagnose and treat it in the future;
5 years
To investigate the molecular pathways related to the development of specific tumors from a biological point of view;
5 years
To investigate the effect of cancer treatment on the tumor, microenvironment and patients globally;
5 years
To collect large series of homogeneous clinical data to analyse the disease course and treatment performed;
5 years
To investigate the prevalence and validate the prognostic or predictive value of novel biomarkers in cancers;
5 years
- +2 more secondary outcomes
Study Arms (5)
RP-1828 IMMUcan (CLOSED for recruitment since August 2024)
The goal is to generate broad molecular and cellular profiling data of the tumour and its microenvironment from cancer patients integrated with clinical data, to understand how the immune system and tumours interact, and the impact of current therapeutic interventions. Tumor types: Thorax, Head and Neck, Breast, Gastrointestinal, Genito Urinary
RP-1759 AYA/TYA (CLOSED for recruitment since December 2021)
The pilot study will be focusing on young adults (12 to 29 years old) with rare cancer to understand better the biology of the tumor in this specific population, and compare it to children and adults with similar disease, as well as to improve the inclusion of young adults into clinical trials. Tumor type: CNS
RP-1843 Arcagen (CLOSED for recruitment since November 2022)
This is a collaborative project between EORTC and EURACAN to perform molecular characterisation of rare cancers patients, using Foundation Medicine tests. The goal of this project is to get a better understanding of the genomic landscape of rare cancers and potentially help define possibilities for targeted treatments/clinical trials for this population. Tumor types: all 10 EURACAN domains
RP-1920 BioRadon
The primary objective is to assess the correlation between the molecular profiles of NSCLC patients and indoor radon concentration, measured with an alpha-particle detector (a standardized and validated way of measuring indoor radon). Tumor type: Thorax
2148 MRD
The main objective of the 2148 Minimal Residual Disease Assessment project is to assess the potential of circulating tumor DNA (ctDNA) as a surrogate marker of recurrence by studying its positive predictive value (PPV). This will help determine how accurately ctDNA can predict cancer recurrence. Tumour type: Head and Neck
Interventions
WES, lcWGS and RNAseq, multiplex IF and IMC
WES, RNAseq and EPIC array
Eligibility Criteria
Patients with pathologically confirmed selected tumor types.
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Sponsors & Collaborators
Study Sites (134)
Medical University Vienna - General Hospital AKH
Vienna, 1090, Austria
Onze Lieve Vrouw Ziekenhuis
Aalst, 9300, Belgium
ZAS Middelheim
Antwerp, 2020, Belgium
Hopitaux Universitaires - Institut Jules Bordet
Brussels, 1000, Belgium
Universitair Ziekenhuis Brussel
Brussels, 1000, Belgium
Cliniques Universitaires Saint-Luc
Brussels, 1200, Belgium
Universitair Ziekenhuis Gent
Ghent, 9000, Belgium
Pole Hospitalier Jolimont - Hopital Jolimont
Haine-Saint-Paul, 7100, Belgium
U.Z. Leuven - Campus Gasthuisberg
Leuven, 3000, Belgium
C.H.U. Sart-Tilman
Liège, 4000, Belgium
Centre Hospitalier Regional De La Citadelle
Liège, 4000, Belgium
CHU Site Sainte-Elisabeth-UCL Namur
Namur, 5000, Belgium
AZ Turnhout - Campus Sint Elisabeth
Turnhout, 2300, Belgium
CHU Mont Godinne - UCL Namur
Yvoir, 5530, Belgium
University Hospital Centre Zagreb
Zagreb, 10000, Croatia
Bank Of Cyprus Oncology Centre
Stróvolos, 2006, Cyprus
University Hospital Motol
Prague, 150 06, Czechia
North Estonia Medical Centre - Mustamäe unit
Tallinn, 13419, Estonia
Centre Hospitalier Avignon
Avignon, 84902, France
CHRU de Besancon - Hopital Jean Minjoz
Besançon, 25030, France
Centre de Radiotherapie Pierre Curie
Beuvry, 62660, France
CHU de Bordeaux - Groupe Hospitalier Saint-Andre - Hopital Saint-Andre
Bordeaux, 33075, France
Institut Bergonie
Bordeaux, 33076, France
Centre Hospitalier - Boulogne Sur Mer
Boulogne-sur-Mer, 62321, France
CHU de Lyon - Hopital Louis Pradel
Bron, 69500, France
CHU Lyon - Hopital neurologique Pierre Wertheimer
Bron, 69677 Cedex, France
Centre Francois Baclesse
Caen, 14076, France
Centre Hopitalier Intercommunal De Creteil
Créteil, 94010, France
Centre Georges-Francois-Leclerc
Dijon, 21079, France
CHU de Grenoble - La Tronche - Hôpital A. Michallon
Grenoble, 38043, France
Centre Hospitalier Departemental Vendee
La Roche-sur-Yon, 85925, France
Centre Oscar Lambret
Lille, 59000, France
CHRU de Lille
Lille, 59037 Cedex, France
CHU de Lyon - Hopital Edouard Herriot
Lyon, 69003, France
Centre Léon Berard
Lyon, 69008, France
CHU de Lyon - Hopital Lyon Sud
Lyon, 69495, France
Assistance Publique - Hopitaux de Marseille - Hopital Nord
Marseille, 13015, France
Centre Hospitalier D'Annecy Genevois
Metz-Tessy, 74370, France
CHU Montpellier-Hopital Arnaud De Villeneuve
Montpellier, 34295 CEDEX 5, France
Institut du Cancer de Montpellier
Montpellier, 34298, France
Centre Hospitalier Des Pays De Morlaix
Morlaix, 29600, France
Centre d'Oncologie de Gentilly
Nancy, 54100, France
CHU de Nice - Hopital De L'Archet
Nice, 06200, France
Assitance Publique - Hopitaux de Paris - Hopital Saint-Louis
Paris, 75010, France
Assistance Publique - Hopitaux de Paris - Hopital Saint Antoine
Paris, 75012, France
Assistance Publique - Hopitaux de Paris - La Pitie Salpetriere
Paris, 75013, France
Institut Curie- Hopital de Paris
Paris, 75248 CEDEX 05, France
Groupe Hospitalier Paris Saint-Joseph - Hopital Saint Joseph
Paris, 75674, France
Centre Eugene Marquis
Rennes, 35042, France
Institut de Cancerologie de l'Ouest (ICO) - Centre Rene Gauducheau
Saint-Herblain, 44805, France
Clinique Mutualiste de l'Estuaire - Centre d'oncologie
Saint-Nazaire, 44600, France
Institut de Cancerologie de la Loire Lucien Neuwirth
Saint-Priest-en-Jarez, 42270, France
Institut de Cancerologie Strasbourg Europe (formar Paul Strauss)
Strasbourg, 67200, France
CHU Toulouse - Hopital Larrey
Toulouse, 31059, France
Gustave Roussy
Villejuif, 94805, France
Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum
Berlin, 13353, Germany
Universitaetsklinikum Carl Gustav Carus
Dresden, 01307, Germany
Universitaetsklinikum Greifswald der Ernst Morizt Arndt Univ. Greifswald AoR
Greifswald, 17475, Germany
Universitaetsklinikum Jena
Jena, 07447, Germany
Onkologie UnterEms, Leer-Papenburg-Emden
Leer, 26789, Germany
NIMTS - Veterans Administration Hospital
Athens, 11521, Greece
Athens University - Attikon University General Hospital
Athens, 12462, Greece
Hygeia Hospital
Athens, 151 23, Greece
Ioannina University Hospital
Ioannina, 45500, Greece
Ospedale Civile Santi Antonio e Biagio e Cesare Arrigo
Alessandria, 15100, Italy
Alma Mater Studiorium Universita di Bologna - Loc. Ospedala Sant'Orsolo
Bologna, 40138, Italy
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
Brescia, 25123, Italy
Azienda Istituti Ospitalieri di Cremona
Cremona, 26100, Italy
IRCCS Azienda Ospedaliera Universitaria San Martino "IST" Istituto Nazionale per la Ricerca sul Cancro
Genova, 16132, Italy
Azienda Unita Locale Socio-Sanitaria N. 9-Mater Salutis Hospital
Legnago, 37045, Italy
IRCCS - Istituto Neurologico Carlo Besta
Milan, 20133, Italy
Azienda Sanitaria Locale Napoli 1 Centro
Naples, 80147, Italy
Universita Di Torino - Ospedale S. Luigi Gonzaga
Orbassano, 10043, Italy
IRCCS - Istituto Oncologico Veneto
Padova, 35128, Italy
Istituti Clinici Scientifici Maugeri
Pavia, 27100, Italy
Regina Elena National Cancer Center
Roma, 00144, Italy
Azienda Ospedaliera Città della Salute e della Scienza di Torino - Ospedale Molinette
Torino, 10126, Italy
Azienda Ospedaliera Città della Salute e della Scienza di Torino - Ospedale San Giovanni - Dipartimento Neuroscienze
Torino, 10126, Italy
Azienda Ospedaliera Città della Salute e della Scienza di Torino - Ospedale Sant'Anna
Torino, 10126, Italy
Lithuanian Oncology Center-Nat. Cancer Inst
Vilnius, 08660, Lithuania
The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis
Amsterdam, 1066 CX, Netherlands
Amsterdam UMC - Locatie AMC
Amsterdam, 1105 AZ, Netherlands
University Medical Center Groningen
Groningen, 9713 GZ, Netherlands
Academisch Ziekenhuis Maastricht
Maastricht, 6202 AZ, Netherlands
Radboud University Medical Center Nijmegen
Nijmegen, 6525GA, Netherlands
Medical University Of Gdansk
Gdansk, 80 211, Poland
Maria S. Curie Memorial Institute-Gliwice Branch
Gliwice, 44-101, Poland
The Great Poland Cancer Centre
Poznan, 61 866, Poland
Maria Sklodowska-Curie Memorial Cancer Centre
Warsaw, Poland
Instituto Portugues De Oncologia - Centro De Coimbra
Coimbra, 3000-075, Portugal
Instituto Portugues de Oncologia de Lisboa Francisco Gentil - EPE
Lisbon, 1099-023 CODEX, Portugal
Hospital CUF Tejo
Lisbon, 1350-352, Portugal
Centro Hospitalar de Lisboa Ocidental- San Francisco Xavier Hospital
Lisbon, 1449-005, Portugal
Hospital CUF Descobertas
Lisbon, 1998-018, Portugal
Centro Hospitalar do Porto- Hospital de Santo Antonio
Porto, 4099-001, Portugal
Instituto Portugues de Oncologia do Porto
Porto, 4200-162, Portugal
Unidade Local de Saúde Gaia e Espinho
Vila Nova de Gaia, 4430, Portugal
Medisprof Cancer Center srl
Cluj-Napoca, Cluj Napoca, 400058, Romania
University Clinic Centre Serbia - Pulmonology clinic
Belgrade, 11000, Serbia
University Clinical Center of Serbia - Clinic for ENT and MFH
Belgrade, 11000, Serbia
University Clinic Golnik
Golnik, 4204, Slovenia
University Medical Center Maribor
Maribor, 2000, Slovenia
ICO L'Hospitalet - Hospital Duran i Reynals (Institut Catala D'Oncologia)
L'Hospitalet de Llobregat, Barcelona, 08908, Spain
Vall d'Hebron Institut d'Oncologia
Barcelona, 08035, Spain
Hospital Clinic Universitari de Barcelona
Barcelona, 08036, Spain
Hospital De La Santa Creu I Sant Pau
Barcelona, 08041, Spain
Hospital General Universitario De Elche
Elche, 03203, Spain
ICO Girona - Hospital Doctor Josep Trueta (Institut Catala D'Oncologia)
Girona, 17007, Spain
ICO L'Hospitalet- Hospital Universitari de Bellvitge
L'Hospitalet de Llobregat, 08907, Spain
Hospital Infantil Universitario Nino Jesus
Madrid, 28009, Spain
Hospital Universitario Infanta Leonor
Madrid, 28031, Spain
Hospital Universitario Ramon y Cajal
Madrid, 28034, Spain
Hospital Universitario San Carlos
Madrid, 28040, Spain
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
Hospital Universitario QuironSalud
Madrid, 28223, Spain
Hospital Universitario Virgen De La Victoria
Málaga, 29010, Spain
Hospital Clinico Universitario De Valencia
Valencia, 46010, Spain
Hospital Clinico Universitario De Valladolid
Valladolid, 47003, Spain
Hospital Clinico Universitaro De Valladolid
Valladolid, 47011, Spain
Hirslanden Klinik-Tumor Zentrum Aarau
Aarau, 5000, Switzerland
Kantonsspital St Gallen
Sankt Gallen, 9007, Switzerland
UniversitaetsSpital Zurich
Zurich, 8091, Switzerland
Betsi Cadwaladr University Health Board - Glan Clwyd District General Hospital
Bodelwyddan, Denbighshire, LL18 5UJ, United Kingdom
University Hospitals Birmingham NHS Foundation Trust (UHB) - UHB-Queen Elisabeth Medical Centre
Birmingham, B15 2TH, United Kingdom
Royal Orthopaedics Hospital, NHS Trust
Birmingham, B312AP, United Kingdom
Cambridge University Hospital NHS - Addenbrookes Hospital
Cambridge, CB2 0QQ, United Kingdom
Velindre NHS Trust - Velindre Cancer Centre
Cardiff, CF14 2TL, United Kingdom
University Hospitals Coventry and Warwickshire NHS Trust - University Hospital
Coventry, CV2 2DX, United Kingdom
NHS Lothian - Western General Hospital
Edinburgh, EH4 2XU, United Kingdom
NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital
Glasgow, G12 OYN, United Kingdom
Hereford County Hospital
Hereford, HR1 2ER, United Kingdom
Leeds Teaching Hospitals NHS Trust - St. James's University Hospital
Leeds, LS9 7TF, United Kingdom
Royal Free Hospital
London, NW3 2QG, United Kingdom
The Christie NHS Foundation Trust
Manchester, M20 4BX, United Kingdom
Biospecimen
FFPE tissue sample; Blood sample; Fresh bone marrow sample (in case of hematological malignancies)
MeSH Terms
Conditions
Study Officials
- STUDY CHAIR
Benjamin Besse, Pr.
European Organisation for Research and Treatment of Cancer - EORTC
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 5 Years
- Sponsor Type
- NETWORK
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 13, 2016
First Posted
July 15, 2016
Study Start
May 3, 2017
Primary Completion
August 29, 2022
Study Completion (Estimated)
October 1, 2031
Last Updated
April 17, 2026
Record last verified: 2026-04